

Carl Eibl

Managing Director

ceibl@epvc.com

Areas of focus:

- Software and Services
- General Business

EMPLOYMENT

- 2003 – Present **Enterprise Partners Venture Capital, San Diego, CA**
Managing Director of a venture capital firm based in San Diego with more than \$1 billion under management and focused on high technology and biotechnology companies.
- 1999 – 2003 **Maxwell Technologies, Inc., San Diego, CA**
Chief Executive Officer of a publicly-held high technology company that develops and sells high-reliability power and microelectronic products in the transportation, telecommunications, consumer and industrial electronics, electric utility infrastructure and medical imaging markets. Led a complete rebuild of Maxwell from a power engineering services company for defense contracting to a product-driven, commercial enterprise using power and radiation shielding technology from the old Maxwell.
- 1999 **Stratagene Corporation, San Diego, CA**
President and Chief Operating Officer of a privately-held biotechnology company that develops and sells DNA, RNA, other biologicals and laboratory instruments in the medical, pharmaceutical and university research markets. Together with Chairman and CEO, lead and completed a restructuring of the Company.
- 1993 – 1999 **Mycogen Corporation, San Diego, CA**
President and Chief Executive Officer of a publicly-held agricultural biotechnology company from 1997 - 1999; President and Chief Operating Officer 1995 - 1997; Executive Vice President 1993 - 1995. Responsible for building business to develop and sell transgenic crops (corn, soybean, sunflower, sorghum and cotton) using Mycogen genetic technology.
- 1995 – 1998, the Company's operating revenue base increased from approximately \$100 million (all in North America) to \$260 million (\$100 million outside North America). Seed revenues increased from \$65 million to \$200 million. The Company also added new core transgenic plant technology platforms (edible vaccines via plants, peptide based disease resistance, modified oil and protein traits, and viral based plant transformation and other enabling technology). Mycogen public market capitalization improved from \$300 million in 1995 to \$1.1 billion at end of 1998 (sale to The Dow Chemical Company).
- 1985 – 1992 **Paul Weiss Rifkind Wharton & Garrison, New York, NY and Brobeck, Phleger & Harrison, San Diego, CA**
Corporate Attorney focused on corporate finance, mergers and acquisitions and technology ventures.

EDUCATION

Boston University School of Law, Boston MA
Jurist Doctor, June 1985

Cornell University, Ithaca, NY
BA in Economics and English Literature, June 1982

Phillips Exeter Academy, Exeter, NH
Graduate, 1978